tbuckley/cabot-search huggingface dataset:
Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial
Authors: Oliver Thomusch, Michael Wiesener, Mirian Opgenoorth, Andreas Pascher, Rainer Peter Woitas, Oliver Witzke, Bernd Jaenigen, Markus Rentsch, Heiner Wolters, Thomas Rath, Tülay Cingöz, Urs Benck, Bernhard Banas, Christian Hugo
Journal: The Lancet (2016)
Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure
Authors: Thomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, Eric Wattel, Francois Dreyfus, Aspasia Stamatoulas, Shanti Ame, Jacques Delaunay, Emmanuel Raffoux, Fatiha Chermat, Pierre Fenaux, Norbert Vey
Journal: Blood (2012)
Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
Authors: Jeffrey Jones, Anthony R. Mato, Steven Coutre, William Wierda, Michael Y. Choi, Matthew S. Davids, Nicole Lamanna, Paul Barr, Kim Burns, Nicholas Montalvo, Ming Zhu, Todd Busman, Jalaja Potluri, Rod A. Humerickhouse, John C. Byrd
Journal: Blood (2015)
SP0114 How To Define and Assess Inflammatory and Destructive Changes in Rheumatoid Arthritis and Psoriatic Arthritis? Including Quiz Cases
Authors: M. Østergaard
Journal: Annals of the Rheumatic Diseases (2016)

Compared to conventional clinical, biochemical and radiographical examinations, magnetic resonance imaging (MRI) offers improved sensitivity to early inflammatory and destructive changes in peripheral joints in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other inflammatory joint diseases. Furthermore, MRI measures provide high sensitivity to change and prognostic value. Accurate and reproducible assessment requires strict definitions and validated assessment methods. Such methods can be qualitative, semiquantitative or quantitative. The present talk will outline currently available definitions and assessment systems of inflammatory and destructive changes in RA and PsA. The most used methods, i.e the RAMRIS (RA MRI scoring system) and PsAMRIS (PsA MRI scoring system), both developed by the OMERACT group, will be described, as will recent alternative approaches including whole-body MRI, dynamic contrast-enhanced MRI and volume quantification. At the end of the talk, quiz cases for audience participation will be presented. <h3>Disclosure of Interest</h3> None declared
Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa, and the Subsequent Generation of a Factor XIIa/Plasma Kallikrein Bispecific Antibody
Authors: Shauna D Mason, Jon Kenniston, Stephen R Comeau, Gregory P Conley, Niksa Kastrapeli, Kris J Kopacz, Allison P Lindberg, Janja Cosic, Monicah Kivaa, James A Qiu, Ryan Faucette, Dan Sexton, Christopher Tenhoor, David Gailani, S. Kent Dickeson, Qiufang Cheng, Michael Wallisch, Andras Gruber, Burt Adelman, Andrew Nixon
Journal: Blood (2015)
Rituximab Combined with Intravenous or Oral Fludarabine for Previously Untreated Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients.
Authors: Antonio Salar, Eva Domingo-Domenech, Cristina Estany, Miguel Canales, Octavio Servitge, Fernando Gallardo, Carmen Pedro, Carlos Montalban
Journal: Blood (2007)
Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,
Authors: Dina Gifkins, Megan McAuliffe, Amy Matcho, Jane Porter, Scott Chavers, Maria Ponsillo, Jay King, Avinash Desai, Andrew Cakana, Dixie-Lee Esseltine
Journal: Blood (2011)
Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.
Authors: Wendy Stock, Samir D. Undevia, Stefan Faderl, Olotoyosi Odenike, Farhad Ravandi, Srdan Verstovsek, Elizabeth Rich, Lucy Godley, Gautam Borthakur, William Wierda, Andrew Artz, Diane Bennett, Jackie Ramirez, Richard A. Larson, Mark J. Ratain, Francis Giles
Journal: Blood (2006)
Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145–e146
Authors: Itamar Raz, Avivit Cahn
Journal: Diabetes Care (2016)

We have read with great interest the analysis by Shahraz et al. (1) regarding the impact of patient characteristics on HbA1c targets.

In recent years, it has been recognized that ameliorating hyperglycemia does not lead to reduced mortality and improved cardiovascular outcomes in the short term. Therefore, the means whereby glucose is controlled and the “cost” of control (i.e., hypoglycemia and medication side effects) must be considered (2). Accordingly, the importance of individualizing glycemic targets and setting safe targets in frail populations has been emphasized in diabetes position statements in recent years (3).

An interesting observation in the analysis by Shahraz et al. (1) is an exceptionally low …
Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)
Authors: Ekta Aneja, Adriana C Rossi, Tomer M Mark, David Jayabalan, Roger Pearse, Karen Pekle, Art Perry, Morton Coleman, Ruben Niesvizky
Journal: Blood (2014)
Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling
Authors: Peter P. Ruvolo, Venkata Lokesh Battula, YiHua Qui, Vivian R Ruvolo, Rodrigo Jacamo, Zhihong Zeng, Rui-Yu Wang, Teresa McQueen, Arvind Rao, SukYoung Yoo, Phuong M Le, Numsen Hail, Bing Z Carter, Steven M. Kornblau, Michael Andreeff
Journal: Blood (2014)
Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Norbert Claude Gorin, Myriam Labopin, Simona Piemontese, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Journal: Blood (2014)
Acute Adult Leukemia (ATL) Successfully Treated with Full Matched Sibling Bone Marrow Transplantation and Haplo-Identical (3 Locus Mis-Matched) Peripheral Stem Cell Transplantation.
Authors: Mitsuru Koike, Yohsinori Suzuki, Yasuyuki Inoue, Takao Suzuki, Kouhei Ogawa, Shigesaburo Miyakoshi, Masayuki Kato, Masatomo Takahashi, Ikuo Miura
Journal: Blood (2006)
Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.
Authors: Myo Htut, Firoozeh Sahebi, George Somlo, Pablo Parker, Chatchada Karanes, Andy Dagis, Susan Hmwe, Tanya Paris, Joyce Murata-Collins, Leslie Popplewell, Joycelynne Palmer, Stephen Forman, Amrita Krishnan
Journal: Blood (2010)
The Intention To Treat Analysis of the Different Post Remission Therapy Modalities in AML Patients with the “Intermediate Risk Group (IPG)” Based on Cytogenetics.
Authors: Yeung-Chul Mun, S.M. Lee, S.H. Park, E.K. Cho, J.H. Lee, D.Y. Jo, I.H. Kim, S.S. Yoon, S.Y. Park, S.M. Bang, Y.J. Min, J.J. Seo, M.H. Lee, C.S. Kim, Y.D. Joo, S.Y. Chung, D.Y. Oh, D.Y. Zang, K.H. Lee, M.S. Hyun, H.S. Song, H.S. Kim, H.C. Kwon, H.J. Kim, Y.H. Park, M.J. Ahn, J.S. Ahn, K.T. Park, S.H. Bae, H.M. Ryoo, H.J. Yoon, B.S. Kim, Thad Ghim, Chu-Myong Seong
Journal: Blood (2006)
Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody
Authors: Michael Aigner, Julian Feulner, Roman Kischel, Peter Kufer, Patrick A Baeuerle, Andreas Mackensen, Stefan W. Krause
Journal: Blood (2010)
ATNT-05INTRAOPERATIVE INTRAPARENCHYMAL INJECTION OF IRINOTECAN DRUG LOADED BEADS IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): A SAFE NEW DEPOT APPROACH FOR LOCO-REGIONAL THERAPY (NCT02433392)
Authors: Garth Cruickshank, Oluwafikayo Fayeye, Desire Ngoga, Juliet Connor, Allah Detta
Journal: Neuro-Oncology (2015)

BACKGROUND: Chemotherapy for brain tumours has been limited because of difficulty in achieving exposure to the tumour without systemic toxicity. Parenteral Irinotecan despite activity against glioma has an uncertain entry into the brain that has questioned its actual efficacy against glioma and a poor profile of enhanced systemic toxicity. In this study we have injected irinotecan sulphonated to PVA beads (1-1000 ) into the brain around tumour following resection of recurrent GBM to assess vehicle and drug safety from disease and procedure related problems. METHODS:10 patients who have failed available therapy for proven recurrent GBM with single focal recurrences as determined by gadolinium enhanced MRI with good performance and ages from 34 -76 were consented for this Phase I study. At operation tumour was removed and the cavity wall injected up to 5mm depth with up to 60 injections of beads suspended in alginate solution delivered using a 24 gauge flexible catheter to a total volume of 3mls and a drug dose of 100mg. Clinical assessments and blood samples were assessed for CTC criteria over 5/7 and imaging and clinical a assessment performed post operation at two and four and eight weekly to 6 months post surgery. RESULTS: To date one (6/15) patient has died at 4/12post treatment of progressive disease and there have been no CTC >2 or procedure related falls in performance despite these patients previous treatment and condition. We have no evidence from this study to suggest any local chemical meningitis or untoward swelling from the injection process. Follow-up is ongoing for survival comparison with other depot therapies. CONCLUSIONS: This novel form of depot therapy offers a stable safe drug loading platform and an accessible generic approach to ensuring local delivery of new agents or those with an uncertain access profile.
METB-06THE GLYCOLYSIS ENZYME GLUCOSE 6-PHOSPHATE ISOMERASE (GPI) STIMULATES GLIOBLASTOMA CELL MOTILITY IN AN AUTOCRINE FASHION
Authors: Annegret Kathagen, Jonathan Weller, Mareike Holz, Alexander Schulte, Manfred Westphal, Katrin Lamszus
Journal: Neuro-Oncology (2015)

The Warburg effect describes the metabolic redirection in tumor cells away from oxidative phosphorylation to aerobic glycolysis, a status even enhanced by hypoxia. We recently discovered an oxygen concentration-dependent reciprocal metabolic switch between glycolysis and the pentose phosphate pathway, which is associated with a pro-migratory as opposed to a pro-proliferative phenotype, respectively (Kathagen et al., Acta Neuropathol 2013). However, the mechanistic link between glycolysis and cell migration is poorly understood. Since the hypoxia-induced glycolytic enzyme glucose 6-phosphate isomerase (GPI) is identical to autocrine motility factor (AMF), a secreted cytokine that binds to the cell surface receptor AMFR, we studied the functional effects of GPI/AMF on glioblastoma cells. Recombinant GPI/AMF strongly stimulated the migration of glioblastoma stem-like (GS) cells in modified Boyden chamber assays and was even more powerful than Hepatocyte Growth Factor/Scatter Factor, a known highly potent glioma cell motogen. In contrast, GPI/AMF moderately reduced the proliferation of GS cells. Erythrose 4-phosphate, an inhibitor of GPI/AMF activity, abrogated the pro-migratory effect of GPI/AMF while having no effect on GS cell proliferation. Gene expression profiling, qPCR and Western Blot analyses revealed a strong upregulation of GPI/AMF as well as of AMFR expression in response to hypoxia. Furthermore, the amount of secreted GPI/AMF in supernatants of GS cells was strikingly increased under hypoxia. GS cell-conditioned medium had a pro-migratory effect on cells, which was abrogated by immunodepletion of GPI/AMF from the culture medium. Knockdown of GPI/AMF expression by shRNA reduced GS cell migration but had no effect on proliferation. Immunostaining of human glioblastoma sections revealed increased expression of both GPI/AMF and AMFR in hypoxic pseudopalisading regions. To conclude, GPI/AMF is an extraordinarily potent motogen for GS cells, which explains in part the association between increased glycolytic activity. GPI/AMF may be thus be a valuable target for inhibiting glioblastoma cell invasion.
Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial
Authors: Hood Thabit, Sara Hartnell, Janet M Allen, Andrea Lake, Malgorzata E Wilinska, Yue Ruan, Mark L Evans, Anthony P Coll, Roman Hovorka
Journal: The Lancet Diabetes & Endocrinology (2016)

We assessed whether fully closed-loop insulin delivery (the so-called artificial pancreas) is safe and effective compared with standard subcutaneous insulin therapy in patients with type 2 diabetes in the general ward.For this single-centre, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes who were receiving insulin therapy. Patients were recruited from general wards at Addenbrooke's Hospital, Cambridge, UK. Participants were randomly assigned (1:1) by a computer-generated minimisation method to receive closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses) or conventional subcutaneous insulin delivery according to local clinical guidelines. The primary outcome was time spent in the target glucose concentration range of 5·6-10·0 mmol/L during the 72 h study period. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01774565.Between Feb 20, 2015, and March 24, 2016, we enrolled 40 participants, of whom 20 were randomly assigned to the closed-loop intervention group and 20 to the control group. The proportion of time spent in the target glucose range was 59·8% (SD 18·7) in the closed-loop group and 38·1% (16·7) in the control group (difference 21·8% [95% CI 10·4-33·1]; p=0·0004). No episodes of severe hypoglycaemia or hyperglycaemia with ketonaemia occurred in either group. One adverse event unrelated to study devices occurred during the study (gastrointestinal bleed).Closed-loop insulin delivery without meal-time boluses is effective and safe in insulin-treated adults with type 2 diabetes in the general ward.Diabetes UK; European Foundation for the Study of Diabetes; JDRF; National Institute for Health Research Cambridge Biomedical Research Centre; Wellcome Trust.
Differences between asthma–COPD overlap syndrome and adult-onset asthma
Authors: Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Lauri Lehtimäki, Jussi Haanpää, Onni Niemelä, Hannu Kankaanranta
Journal: European Respiratory Journal (2017)

Differences between asthma–COPD overlap syndrome (ACOS) and adult-onset asthma are poorly understood. This study aimed to evaluate these differences in a clinical cohort of patients with adult-onset asthma, as a part of the Seinäjoki Adult Asthma Study (SAAS). 188 patients were diagnosed with adult-onset asthma and re-evaluated 12 years after diagnosis. They were divided into three groups based on smoking history and post bronchodilator spirometry values: 1) never- and ex-smokers with &lt;10 smoked pack-years; 2) non-obstructive (forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) ≥0.7) patients with ≥10 pack-years; and 3) ACOS patients with ≥10 pack-years and FEV 1 /FVC &lt;0.7. ACOS patients had lower diffusing capacity ( D LCO /V A 86% predicted versus 98 or 96% predicted; p&lt;0.001), higher blood neutrophil levels (4.50 versus 3.60 or 3.85×10 9 L −1 ; p=0.008), and higher IL-6 levels (2.88 versus 1.52 or 2.10 pg·mL −1 , p&lt;0.001) as compared to never- and ex-smokers with &lt;10 pack-years, or non-obstructive patients with ≥10 pack-years smoking history, respectively. ACOS patients also showed reduced lung function, higher remaining bronchial reversibility and a higher number of comorbidities. This study shows distinct differences in diffusing capacity, blood neutrophil and IL-6 levels, bronchial reversibility, lung function and comorbidities between ACOS and adult-onset asthma. The present findings should be considered in the comprehensive assessment of adult asthma patients.
Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP
Authors: Andrew M. Evens, Laurie H. Sehn, Pedro Farinha, Paul T Schumacker, Adekunle Raji, Yi Lu, Beverly P. Nelson, Randy D. Gascoyne, Leo I. Gordon
Journal: Blood (2008)
WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.
Authors: Carlo Messina, Cristina Tresoldi, Maria Teresa Lupo Stanghellini, Alessandro Crotta, Stefania Girlanda, Milena Coppola, Simona Piemontese, Raffaella Greco, Simona Malato, Barbara Forno, Andrea Assanelli, Daniela Clerici, Sara Mastaglio, Fabio Giglio, Marta Bruno Ventre, Francesca Lunghi, Elena Guggiari, Matteo Giovanni Carrabba, Magda Marcatti, Consuelo Corti, Chiara Bonini, Katharina Fleischhauer, Jacopo Peccatori, Claudio Bordignon, Fabio Ciceri, Massimo Bernardi
Journal: Blood (2009)
Noncanonical Fungal Autophagy Inhibits Inflammation in Response to IFN-γ via DAPK1
Authors: Vasilis Oikonomou, Silvia Moretti, Giorgia Renga, Claudia Galosi, Monica Borghi, Marilena Pariano, Matteo Puccetti, Carlo A. Palmerini, Lucia Amico, Alessandra Carotti, Lucia Prezioso, Angelica Spolzino, Andrea Finocchi, Paolo Rossi, Andrea Velardi, Franco Aversa, Valerio Napolioni, Luigina Romani
Journal: Cell Host & Microbe (2016)
Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience
Authors: Pau Abrisqueta, Francesc Bosch, Marta Aymerich, Eva Gine, Carol Moreno, Maria Rozman, Neus Villamor, Elias Campo, Ciril Rozman, Emili Montserrat
Journal: Blood (2008)
Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism
Authors: Xin-Yan Pei, Michael W Sanderson, Leena E Youssefian, Jessica Felthousen, Lora B Kramer, Yun Dai, Steven Grant
Journal: Blood (2014)
THU0097 Descriptive Analysis of Large Single Center Experience of Patients with Interstitial Lung Disease and Rheumatoid Arthritis: Table 1.
Authors: J.A. Zamora-Legoff, C.S. Crowson, M.L. Krause, E.L. Matteson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ILD may present as a rare but serious extraarticular manifestation in patients with RA and can have dramatic effect on morbidity and mortality. <h3>Objectives</h3> To evaluate the course of pulmonary disease in a large prevalence cohort of patients with RA who have ILD. <h3>Methods</h3> Prevalent cases of RA with ILD from 01/01/1998 to 01/01/2014 were identified in a single center9s electronic medical record using advanced software to identify cases using ICD-9 diagnosis codes. All cases were manually reviewed and screened for inclusion. RA characteristics and pulmonary findings including high-resolution computed tomography (HRCT) and pulmonary function testing (PFT) were evaluated. Descriptive statistics were used to summarize the data. <h3>Results</h3> Two-hundred and one patients with ILD and RA were identified. Patients were predominately Caucasian (97%); 54% were males; mean age was 66.6 years (±10.9) at ILD diagnosis. Mean follow-up from ILD diagnosis was 4.1 years (±4.0) and median time from RA to ILD diagnosis was 4.9 (range -15.7 to 45.6) years. Seventy-three (37%) were never smokers. Eighty-seven (43%) had usual interstitial pneumonia (UIP) and/or idiopathic pulmonary fibrosis (IPF) and sixty-seven (33%) had non-specific interstitial pneumonia (NSIP) by HRCT. Anti-citrullinated protein antibody (ACPA) was present in 110 (77%) of 142 tested patients, and rheumatoid factor (RF) was present in 161 (84%). Erosive disease was present in 52 (28%) of patients and 103 (51%) had other extraarticular manifestations of RA prior to or at time of ILD diagnosis. The baseline predicted PFTs at time of ILD diagnosis included a forced vital capacity (FVC) of 72% (± 21), a forced expiratory volume in 1 second (FEV1) of 71% (±21), and a diffusing capacity for carbon monoxide (DLCO) of 55% (±19). Ninety-four (49%) patients required supplemental oxygen with a mean requirement at last followup of 2.9 liters (±1.6). At last follow-up 79 had died, with pulmonary disease accounting for 23 (29%) of deaths. <h3>Conclusions</h3> In this largest single-center reported cohort of patients with RA-ILD, most patients were seropositive, male, and had a prior history of tobacco use. UIP was more common than NSIP. Almost half of patients required supplement oxygen, and nearly one third died from pulmonary disease which was the most common known cause of death. <h3>Disclosure of Interest</h3> None declared
ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study
Authors: Antonio G. Piga, Silverio Perrotta, Angela Melpignano, Caterina Borgna-Pignatti, Ersi Voskaridou, Vincenzo Caruso, Aldo Filosa, Yesim Aydinok, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
Journal: Blood (2014)
Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.
Authors: Ping Chen, William Blum, Josephine Aimiuwu, Vijayasarathi Upadhyayula, Zhongfa Liu, Shujun Liu, Jiuxia Pang, Alison Walker, Rebecca B. Klisovic, Ramiro Garzon, Michael R. Grever, Miguel Villalona-Calero, John C. Byrd, Kenneth K Chan, Guido Marcucci
Journal: Blood (2009)
NIMG-75THE ADVANTAGE OF ADVANCED MR IMAGING TECHNIQUES FOR THE DIAGNOSIS OF GERMINOMA
Authors: Fumiyuki Yamasaki, Yasuyuki Kinoshita, Takeshi Takayasu, Satoshi Usui, Ryo Nosaka, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2015)

Intracranial germinomas are rare and account for only 1.9% of primary intracranial tumors in Japan. The diagnosis of germinoma by conventional MR imaging is sometimes difficult. It has not been well documented about the advanced imaging of germinoma. The purpose of our study was to determine if advanced MR imagings could give additional information for differential diagnosis of germinoma. We retrospectively reviewed the imaging of 23 patients with primary central nervous system germinoma who were treated in our institution between Oct 2004 and November 2014. 22 patients were diagnoses by histological specimen and one case was diagnosed by imaging and increase of serum and cerebrospinal fluid hCG-β. Patients underwent conventional MR imaging and advanced MR imaging including diffusion-weighted imaging and single voxel proton MR spectroscopy. Patients age was ranging from 9 to 37-years-old (average 16.1, median 14). 21 were male, and 3 were female patients. Serum hCG-β was elevated at 20 of 23 patients. Cerebrospinal fluid hCG-β was elevated in 15 of 16 examined patients. 13 patients had single lesion, while 10 had multiple lesions, and 3 had disseminated disease. 5 of 23 tumors showed spontaneous regression after biopsy. Bithalamic extension was observed in 10 of 14 patients with pineal germinoma, but only 3 of 10 patients showed edema at thalamus. The cyst formation was observed at 11 of 23 patients. 18 of 21 examined tumors showed high intensity on diffusion-weighted imaging. High lipids peak at single voxel proton MR spectroscopy was observed in 13 of 13 examined tumors. However, other patients could not perform MR spectroscopy because of small tumor size. In conclusions, high intense on diffusion-weighted imaging and high lipids peak at single voxel proton MR spectroscopy might be the characteristics of germinoma.